NorthRock Partners’s Quest Diagnostics DGX Stock Holding History

NorthRock Partners’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,363	Closed	-$260K	–	697
2025 Q3	$260K	Buy	+1,363	New	+$242K	﹤0.01%	747

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

NorthRock Partners's DGX Position: Q4 2025 in Review

NorthRock Partners sold out of Quest Diagnostics (DGX) in Q4 2025, closing a stake of 1,363 shares — an estimated $260K sold.

NorthRock Partners first reported a position in DGX in Q3 2025 and held it in 1 quarter. The position peaked at $260K in Q3 2025. 1,050 funds tracked by Wall St. Rank hold DGX as of Q4 2025.

NorthRock Partners reported no remaining Quest Diagnostics position as of Q4 2025 after selling out during the quarter.
NorthRock Partners sold 1,363 Quest Diagnostics shares in Q4 2025, an estimated $260K.
NorthRock Partners first reported a position in Quest Diagnostics in Q3 2025 and held it in 1 quarter.
NorthRock Partners's Quest Diagnostics position peaked at $260K in Q3 2025.
1,050 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2025.

Based on NorthRock Partners's 13F filing for Q4 2025, filed 17 Feb 2026.